EpiScreen® 2.0: Smarter Immunogenicity Testing

To avoid issues later in the drug development process, you need to start smart.

Home – Solutions – EpiScreen® 2.0: Smarter Immunogenicity Testing

Accurate assessment of immunogenicity can make or break the success of protein therapeutics. Traditional assays often lack the sensitivity, and specificity required. Next-generation EpiScreen® 2.0 is Abzena’s innovative answer to these challenges, utilizing flow cytometry technology for precise, multi-dimensional immunogenicity assays.

EpiScreen® 2.0 Info Sheet: Immunogenicity testing evolved

Our enhanced bioassay platform EpiScreen® 2.0, is a comprehensive suite of assays that predict and evaluate potential risks of preclinical immunogenicity in protein, antibody, and gene therapy therapeutics.

Our next-generation platform provides a better immunogenic assessment. An assessment that is highly sensitive, multi-parametric, and data-rich, which ultimately improves candidate selection and de-risks early-phase development for our customers.

Whitepaper: Immunogenicity testing evolved with EpiScreen®

Request your copy


Optimizing your immunogenicity assays

To avoid issues later in the drug development process, it is important to start smart with more data-rich assays. We have recently introduced our next-generation EpiScreen® 2.0 technology to elevate the immunogenicity evaluation of protein therapeutics. EpiScreen® 2.0 is high sensitivity and a multi-dimensional, data-rich platform that streamlines the candidate selection helping de-risk the drug development process.

Immunogenicity Assays

Move your drug development program forward, at less risk, with EpiScreen® 2.0

EpiScreen® 2.0 delivers all the required sensitivity, plus detailed data on specificity and mechanism of action, without the need for radioactive markers.

Contact Us